No connection

Search Results

ADMA vs IRTC

ADMA
ADMA Biologics, Inc.
BEARISH
Price
$15.15
Market Cap
$3.61B
Sector
Healthcare
AI Confidence
85%
IRTC
iRhythm Holdings, Inc.
NEUTRAL
Price
$115.24
Market Cap
$3.72B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ADMA
25.25
IRTC
--
Forward P/E
ADMA
10.98
IRTC
137.79
P/B Ratio
ADMA
7.55
IRTC
24.37
P/S Ratio
ADMA
7.07
IRTC
4.98
EV/EBITDA
ADMA
18.04
IRTC
-126.66

Profitability

Gross Margin
ADMA
57.38%
IRTC
70.57%
Operating Margin
ADMA
45.09%
IRTC
4.2%
Profit Margin
ADMA
28.8%
IRTC
-5.96%
ROE
ADMA
35.56%
IRTC
-36.57%
ROA
ADMA
21.5%
IRTC
-2.36%

Growth

Revenue Growth
ADMA
18.4%
IRTC
27.1%
Earnings Growth
ADMA
-52.8%
IRTC
--

Financial Health

Debt/Equity
ADMA
0.17
IRTC
4.79
Current Ratio
ADMA
6.71
IRTC
4.63
Quick Ratio
ADMA
3.54
IRTC
4.34

Dividends

Dividend Yield
ADMA
--
IRTC
--
Payout Ratio
ADMA
0.0%
IRTC
0.0%

AI Verdict

ADMA BEARISH

ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.

Strengths
Exceptional gross and operating margins (57.38% and 45.09%) indicate strong pricing power and cost control
High ROE of 35.56% demonstrates efficient use of equity capital
Low debt/equity ratio of 0.17 and high current ratio of 6.71 signal strong financial stability
Risks
Piotroski F-Score of 3/9 indicates weak financial health and high distress risk
Earnings have declined sharply by 52.8% YoY, contradicting revenue growth of 18.4%
Insider selling of $1.58M in six months, including multiple large sales by the CEO, signals lack of confidence
IRTC NEUTRAL

IRTC presents a stark contrast between fundamental health and growth potential, anchored by a weak Piotroski F-Score of 2/9. While the company demonstrates strong top-line revenue growth (27.1%) and impressive gross margins (70.57%), it is burdened by a high Debt/Equity ratio of 4.79 and a prohibitively expensive Forward P/E of 137.79. Recent earnings beats and a shift toward positive EPS provide a bullish catalyst, but these are offset by bearish insider activity and a complete lack of technical momentum. The stock is currently a speculative growth play rather than a value investment.

Strengths
Strong revenue growth of 27.10% YoY
High gross margins at 70.57%
Recent trend of beating earnings estimates (3/4 last quarters)
Risks
Critically low Piotroski F-Score (2/9) indicating poor financial health
Extreme valuation with a Forward P/E of 137.79 and Price/Book of 24.37
High leverage with a Debt/Equity ratio of 4.79

Compare Another Pair

ADMA vs IRTC: Head-to-Head Comparison

This page compares ADMA Biologics, Inc. (ADMA) and iRhythm Holdings, Inc. (IRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile